Symphogen A/s

Les Laboratoires Servier

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

K&oslash;benhavns Universitet

Michael Kragh

Mikkel Wandahl Pedersen

Klaus Koefoed

Helle Jane Jacobsen

Ivan David Horak

Thomas Bouquin

Johan Lantto

Michael Monrad Grandal

Gunther Roland Galler

Monika Gad

Torben Gjetting

Camilla Fröhlich

Thomas Tuxen Poulsen

Kim Vilbour Andersen

Peter Sejer Andersen

Magnus Strandh

Trine Lindsted

Vikram Kjøller Bhatia

Ida K Christensen

Lars Søgaard Nielsen

Paul E G Kristjansen

Karsten Wessel Eriksen

Paolo Conrotto

Ida Kjaer

Ida Kjær

Adam S Hey

Lars Sogaard Nielsen

Camilla Frohlich

Bj&oslash;rn Quistorff

Eva Maria Carlsen Melander

Eva Maria Melander

Helle Jacobsen

This invention relates to anti-PD-1 antibodies and methods of using them in treating diseases and conditions related to PD-1 activity, e.g., cancer.

Anti-PD-1 antibodies and compositions

This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in the therapies. The therapies are useful in treating diseases such as cancers.

Combination therapies targeting PD-1, TIM-3, and LAG-3

This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.

Anti-lag-3 antibodies and compositions

Anti-LAG-3 antibodies and compositions

This invention relates to anti-TIM-3 antibodies and antibody compositions and their use in enhancing immunity in a patient, e.g., to treat cancer.

Anti-TIM-3 antibodies and compositions

The present invention relates to novel recombinant antibodies directed against human MET (c-MET), as well as compositions comprising mixtures of at least two of said antibodies and use of the antibodies and antibody compositions for treatment of MET-mediated disorders such as cancer.

Anti-MET antibodies and compositions

The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.

Pan-HER antibody composition

The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.

Methods for treating cancer by administering humanized pan-HER antibody compositions

Humanized pan-HER antibody compositions

The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumors following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumors. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.

Methods using recombinant anti-epidermal growth factor receptor antibody compositions

The present invention relates to a method for non-invasive local quantification of angiogenesis or destruction of existing blood vessels in living tissue, the use of the said method for local measurements of hemoglobin concentration and blood perfusion at the same location on the subject and an apparatus for carrying out the method according to the invention. The apparatus comprises a xenon flash unit, an optical filter and a Y-shaped optical fiber-bundle, one branch of the fiber-bundle being coupled to the flash unit and the other branch of the fiber-bundle being coupled to a detection unit and the merged part of the fiber-bundle being adapted to couple the apparatus to the tissue to be tested.

Method and apparatus for non-invasive detection of angiogenic and anti-angiogenic activity in living tissue

Growing community of inventors

Copenhagen, Denmark

Michael Kragh